Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial
Open Access
- 21 June 2020
- journal article
- research article
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 7 (1) , e000577
Abstract
Background: Increased iron availability modifies cardiorespiratory function in healthy volunteers and improves exercise capacity and quality of life in patients with heart failure or pulmonary hypertension. We hypothesised that intravenous iron would produce improvements in oxygenation, exercise capacity and quality of life in patients with chronic obstructive pulmonary disease (COPD). Methods: We performed a randomised, placebo-controlled, double-blind trial in 48 participants with COPD (mean±SD: age 69±8 years, haemoglobin 144.8±13.2 g/L, ferritin 97.1±70.0 µg/L, transferrin saturation 31.3%±15.2%; GOLD grades II–IV), each of whom received a single dose of intravenous ferric carboxymaltose (FCM; 15 mg/kg bodyweight) or saline placebo. The primary endpoint was peripheral oxygen saturation (SpO2) at rest after 1 week. The secondary endpoints included daily SpO2, overnight SpO2, exercise SpO2, 6 min walk distance, symptom and quality of life scores, serum iron indices, spirometry, echocardiographic measures, and exacerbation frequency. Results: SpO2 was unchanged 1 week after FCM administration (difference between groups 0.8%, 95% CI −0.2% to 1.7%). However, in secondary analyses, exercise capacity increased significantly after FCM administration, compared with placebo, with a mean difference in 6 min walk distance of 12.6 m (95% CI 1.6 to 23.5 m). Improvements of ≥40 m were observed in 29.2% of iron-treated and 0% of placebo-treated participants after 1 week (p=0.009). Modified MRC Dyspnoea Scale score was also significantly lower after FCM, and fewer participants reported scores ≥2 in the FCM group, compared with placebo (33.3% vs 66.7%, p=0.02). No significant differences were observed in other secondary endpoints. Adverse event rates were similar between groups, except for hypophosphataemia, which occurred more frequently after FCM (91.7% vs 8.3%, p<0.001). Conclusions: FCM did not improve oxygenation over 8 weeks in patients with COPD. However, this treatment was well tolerated and produced improvements in exercise capacity and functional limitation caused by breathlessness. These effects on secondary endpoints require confirmation in future studies. Trial registration number: ISRCTN09143837.Keywords
Funding Information
- National Institute for Health Research (NIHR) Oxford Biomedical Research Centre
This publication has 40 references indexed in Scilit:
- Six-Minute-Walk Test in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyNew England Journal of Medicine, 2009
- Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12Thorax, 2009
- Development and first validation of the COPD Assessment TestEuropean Respiratory Journal, 2009
- The increase in pulmonary arterial pressure caused by hypoxia depends on iron statusThe Journal of Physiology, 2008
- The MRC breathlessness scaleOccupational Medicine, 2008
- Mitochondrial dysfunction in COPD patients with low body mass indexEuropean Respiratory Journal, 2006
- The St George's Respiratory QuestionnaireRespiratory Medicine, 1991
- Evaluation of Clinical Methods for Rating DyspneaChest, 1988
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983